---
title: "Sun-Novo: The first-instance judgment of the lawsuit requires Hang Seng Pharmaceutical to pay 2.4032 million yuan"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/263967646.md"
description: "Sun-Novo announced that Hang Seng Pharmaceutical needs to pay 2.4032 million yuan to the company due to the first-instance judgment result. In the judgment, Hang Seng Pharmaceutical is required to pay 4.4032 million yuan for research and development expenses and compensation, while Sun-Novo needs to compensate 2 million yuan. The case acceptance fee is borne by Hang Seng Pharmaceutical at 74,500 yuan, and Sun-Novo at 48,000 yuan. The company has fully accrued bad debt provisions, so the lawsuit has no negative impact on profits, and the case is still within the appeal period"
datetime: "2025-11-03T08:40:32.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/263967646.md)
  - [en](https://longbridge.com/en/news/263967646.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/263967646.md)
---

# Sun-Novo: The first-instance judgment of the lawsuit requires Hang Seng Pharmaceutical to pay 2.4032 million yuan

Sun-Novo announced that, as the defendant and counterclaimant, the first-instance judgment of the lawsuit requires Hang Seng Pharmaceutical to pay the company a total of RMB 4.4032 million for research and development expenses and remuneration, while the company is to compensate Hang Seng Pharmaceutical RMB 2 million. After offsetting, Hang Seng Pharmaceutical still needs to pay RMB 2.4032 million. The total case acceptance fee for both the main lawsuit and the counterclaim is RMB 122,500, of which Hang Seng Pharmaceutical bears RMB 74,500 and the company bears RMB 48,000. Since the company has fully provided for bad debt reserves for the relevant accounts receivable, this lawsuit has no negative impact on the current and future profits. The case is currently in the appeal period, and the final impact will be subject to the actual execution situation

### Related Stocks

- [688621.CN](https://longbridge.com/en/quote/688621.CN.md)

## Related News & Research

- [10:19 ETAARC-360 Completes AICPA Peer Review with Pass Rating](https://longbridge.com/en/news/286929747.md)
- [Europe-China spacecraft launches to study Earth's 'invisible armour'](https://longbridge.com/en/news/286881963.md)
- [Finsbury Growth & Income Trust Director Reinvests Dividends into Company Shares](https://longbridge.com/en/news/286940848.md)
- [Atea named CDP Supplier Engagement Assessment A List leader](https://longbridge.com/en/news/287007462.md)
- [CertifID Launches New Client Experience to Simplify Real Estate Transactions](https://longbridge.com/en/news/286944337.md)